Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (71-80 of 332) with videos related to

Pageof 34
Sort By:
Plos One|July 30, 2011
Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsJason A Bailey, Balmiki Ray, Nigel H Greig, et al.
Journal of Neuroscience Research|February 3, 2015
Tumor necrosis factor-α potentiates long-term potentiation in the rat dentate gyrus after acute hypoxiaAudrey M Wall, Gatambwa Mukandala, Nigel H Greig, et al.
The Biochemical Journal|March 7, 2012
Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving groupCecilia Bartolucci, Jure Stojan, Qian-sheng Yu, et al.
The Lancet. Psychiatry|August 8, 2015
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Robert E Becker, Mary V Seeman, Nigel H Greig, et al.
Current Neuropharmacology|August 4, 2025
Advancing Alzheimer's Diagnosis with AI-Enhanced MRI: A Review of Challenges and ImplicationsZahra Batool, ShanShan Hu, Mohammad Amjad Kamal, et al.
International Journal of Molecular Sciences|April 29, 2009
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementDavid Olivares, Xudong Huang, Lars Branden, et al.
The Journal of Clinical Investigation|February 16, 2026
The promise of GLP-1 receptor agonists for neurodegenerative diseasesDilan Athauda, Nigel H Greig, Wassilios G Meissner, et al.
The Open Biochemistry Journal|July 28, 2011
Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of InflammationDavid Tweedie, Kathryn A Frankola, Weiming Luo, et al.
CNS & Neurological Disorders Drug Targets|June 13, 2025
Zebrafish-Based Parkinson's Disease Models: Unveiling Genetic Mechanisms and Therapeutic PathwaysRohinee Dodiya, Pratishtha Sharma, Dipa Israni, et al.
Neuropharmacology|May 22, 2018
Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?Christian Hölscher, Fernanda G De Felice, Nigel H Greig, et al.
Pageof 34

Showing results (71-80 of 332) with videos related to

Sort By:
Pageof 34
Plos One|July 30, 2011
Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsJason A Bailey, Balmiki Ray, Nigel H Greig, et al.
Journal of Neuroscience Research|February 3, 2015
Tumor necrosis factor-α potentiates long-term potentiation in the rat dentate gyrus after acute hypoxiaAudrey M Wall, Gatambwa Mukandala, Nigel H Greig, et al.
The Biochemical Journal|March 7, 2012
Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving groupCecilia Bartolucci, Jure Stojan, Qian-sheng Yu, et al.
The Lancet. Psychiatry|August 8, 2015
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Robert E Becker, Mary V Seeman, Nigel H Greig, et al.
Current Neuropharmacology|August 4, 2025
Advancing Alzheimer's Diagnosis with AI-Enhanced MRI: A Review of Challenges and ImplicationsZahra Batool, ShanShan Hu, Mohammad Amjad Kamal, et al.
International Journal of Molecular Sciences|April 29, 2009
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementDavid Olivares, Xudong Huang, Lars Branden, et al.
The Journal of Clinical Investigation|February 16, 2026
The promise of GLP-1 receptor agonists for neurodegenerative diseasesDilan Athauda, Nigel H Greig, Wassilios G Meissner, et al.
The Open Biochemistry Journal|July 28, 2011
Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of InflammationDavid Tweedie, Kathryn A Frankola, Weiming Luo, et al.
CNS & Neurological Disorders Drug Targets|June 13, 2025
Zebrafish-Based Parkinson's Disease Models: Unveiling Genetic Mechanisms and Therapeutic PathwaysRohinee Dodiya, Pratishtha Sharma, Dipa Israni, et al.
Neuropharmacology|May 22, 2018
Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?Christian Hölscher, Fernanda G De Felice, Nigel H Greig, et al.
Pageof 34